In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announce the following meeting of the aforementioned committee:
Times and Dates:
8 a.m.-6 p.m., February 23, 2011.
8 a.m.-5 p.m., February 24, 2011.
Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton Road, NE., Building 19, Kent “Oz” Nelson Auditorium, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
Purpose: The committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.
Matters To Be Discussed: The agenda will include discussions on: immunization of healthcare personnel; Japanese encephalitis vaccine; 13-valent pneumococcal conjugate vaccine; human papillomavirus (HPV) vaccines; human immunodeficiency virus (HIV); hepatitis B vaccine; pertussis vaccine; influenza; herpes zoster vaccine. Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Stephanie B. Thomas, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road, NE., Mailstop E-05, Atlanta, Georgia 30333, Telephone: (404) 639-8836, Fax: (404) 639-8905, e-mail firstname.lastname@example.org.
The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry.Start Signature
Dated: January 20, 2011.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.
[FR Doc. 2011-1737 Filed 1-26-11; 8:45 am]
BILLING CODE 4160-18-P